Compare ALEMBIC PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WOCKHARDT ALEMBIC PHARMA/
WOCKHARDT
 
P/E (TTM) x 14.8 -23.8 - View Chart
P/BV x 3.4 1.3 272.4% View Chart
Dividend Yield % 1.1 0.0 36,283.4%  

Financials

 ALEMBIC PHARMA   WOCKHARDT
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
WOCKHARDT
Mar-18
ALEMBIC PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs6641,012 65.6%   
Low Rs412532 77.6%   
Sales per share (Unadj.) Rs208.7355.9 58.7%  
Earnings per share (Unadj.) Rs31.0-60.3 -51.4%  
Cash flow per share (Unadj.) Rs37.1-46.8 -79.4%  
Dividends per share (Unadj.) Rs5.500.01 55,000.0%  
Dividend yield (eoy) %1.00 78,867.1%  
Book value per share (Unadj.) Rs144.2257.8 55.9%  
Shares outstanding (eoy) m188.52110.63 170.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.2 118.9%   
Avg P/E ratio x17.4-12.8 -135.6%  
P/CF ratio (eoy) x14.5-16.5 -87.9%  
Price / Book Value ratio x3.73.0 124.7%  
Dividend payout %17.70 -106,951.6%   
Avg Mkt Cap Rs m101,46185,379 118.8%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m7,4679,371 79.7%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m39,34739,369 99.9%  
Other income Rs m941,202 7.8%   
Total revenues Rs m39,44140,571 97.2%   
Gross profit Rs m8,73618 47,736.6%  
Depreciation Rs m1,1521,495 77.1%   
Interest Rs m1842,555 7.2%   
Profit before tax Rs m7,493-2,830 -264.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,568257 609.9%   
Profit after tax Rs m5,844-6,669 -87.6%  
Gross profit margin %22.20 47,763.5%  
Effective tax rate %20.9-9.1 -230.3%   
Net profit margin %14.9-16.9 -87.7%  
BALANCE SHEET DATA
Current assets Rs m19,57733,796 57.9%   
Current liabilities Rs m14,89626,917 55.3%   
Net working cap to sales %11.917.5 68.1%  
Current ratio x1.31.3 104.7%  
Inventory Days Days9079 113.1%  
Debtors Days Days4589 50.8%  
Net fixed assets Rs m27,09739,664 68.3%   
Share capital Rs m377553 68.1%   
"Free" reserves Rs m26,81127,968 95.9%   
Net worth Rs m27,18828,522 95.3%   
Long term debt Rs m4,99321,731 23.0%   
Total assets Rs m47,77881,620 58.5%  
Interest coverage x41.7-0.1 -38,785.6%   
Debt to equity ratio x0.20.8 24.1%  
Sales to assets ratio x0.80.5 170.7%   
Return on assets %12.6-5.0 -250.3%  
Return on equity %21.5-23.4 -91.9%  
Return on capital %23.6-7.7 -307.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4539,807 198.4%   
Fx outflow Rs m6,0651,789 339.1%   
Net fx Rs m13,3888,019 167.0%   
CASH FLOW
From Operations Rs m8,120684 1,186.4%  
From Investments Rs m-7,5566,302 -119.9%  
From Financial Activity Rs m590-7,695 -7.7%  
Net Cashflow Rs m1,153-664 -173.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 2.3 126.1%  
FIIs % 9.1 7.7 118.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 13.9 15.4 90.3%  
Shareholders   49,328 67,757 72.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 17, 2019 03:35 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS